Clinical and microbiological efficacy of colistin therapy alone or in combination as treatment for multidrug resistant Pseudomonas aeruginosa diabetic foot infections with or without osteomyelitis

Journal of Chemotherapy

Volumn 18, Issue 6, 2006, Pages 648-651

  Tascini, Carlo ^a   Gemignani, G ^a   Palumbo, F ^a   Leonildi, A ^a   Tedeschi, A ^a   Lambelet, P ^b   Lucarini, A ^c   Piaggesi, A ^a   Menichetti, F ^a  

^a UNIVERSITY HOSPITAL OF PISA   (Italy)

^b Ospedale Unico Della Versilia   (Italy)

^c Infectious Diseases Service   (Italy)

Author keywords

Colistin; Diabetic foot infection; Imipenem; Osteomyelitis; Pseudomonas aeruginosa; Rifampin

Indexed keywords

COLISTIN; IMIPENEM; RIFAMPICIN;

ACUTE KIDNEY FAILURE; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DIABETIC FOOT; DRUG ACTIVITY; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; HUMAN; IN VITRO STUDY; LUNG EDEMA; MALE; MONOTHERAPY; MULTIDRUG RESISTANCE; OSTEOMYELITIS; PREVALENCE; PSEUDOMONAS AERUGINOSA; REVASCULARIZATION;

EID: 33845993603     PISSN: 1120009X     EISSN: None     Source Type: Journal    
DOI: 10.1179/joc.2006.18.6.648     Document Type: Article

References (12)

1. Ulbrecht JS, Cavanagh PR, Caputo GM. Foot problems in diabetes: an overview. Clin Infect Dis 2004;39:S73-82.
2. Lipsky BA. Medical treatment of diabetic foot infections. Clin Infect Dis 2004;39:5104-14.
3. Falagas ME, Kasiakou SK. Colistin: the revival of polymyxins for the management of multidrug-resistant gram-negative bacterial infections. Clin Infect Dis 2005;40:13331341.
4. Brown JM, Dorman DC, Roy LP. Acute renal failure due to overdosage of colistin. Med J Aust 1970;2:923-4.
5. Koch-Weser J, Sidel VW, Federman EB, Kanarek P, Finer DC, Eaton AE. Adverse effects of sodium colistimethate: manifestations and specific reaction rates during 317 courses of therapy. Ann Intern Med 1970;72:857-68.
6. Falagas ME, Blitziotis IA, Kasiakou SK, Samonis G, Athanassopoulou P, Michalopoulos A. Outcome of infections due to pandrug-resistant (PDR) gram-negative bacteria. BMC Infect Dis 2005;5:24.
7. Caputo GM, Cavanagh PR, Ulbrect JS, Gibbons GW, Karchmer AW. Assessment and management of foot disease in patients with diabetes. N Engl J Med 1994;331:854-60
8. Piaggesi A, Schipani E, Campi F, Romanelli M, Baccetti F, Arvia C, Navalesi R. Conservative surgical approach versus non-surgical management for diabetic neuropathic foot ulcers: a randomized trial. Diabet Med 1998; 15:412-7.
9. Tascini C, Gemignani G, Ferranti S et al. Microbiological activity and clinical efficacy of a colistin and rifampin combination in multidrug-resistant P. aeruginosa infections. J Chemother 2004;16:282-7.
10. Marques MB, Brookings ES, Moser A, et al. Comparative in vitro antimicrobial susceptibilities of nosocomial isolates of Acinetobacter baumannii and synergistic activities of nine antimicrobial combinations. Antimicrob Agents Chemother 1997;41:881-5.
11. Paterson DL, Cornaglia G, Mazzariol A, Lamonaca V, Gruttadauria S, Marino I. A true return to the pre-antibiotic era? Endovascular infections as sequelae of bacteremia with Pseudomonas aeruginosa producing VIM-1, resistant to carbapenems, cephalosporins, penicillins, quinolones and aminoglycosides. In Program and Abstracts of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, MI, 2002. American Society for Microbiology, Washington, DC. 2002: Abstract K1183, p. 406.
12. Tascini C, Ferranti S, Messina F, Menichetti F. In vitro and in vivo synergistic activity of colistin, rifampin and amikacin against a multidrug resistant P. aeruginosa. Clin Microbiol Infect 2000;6:690-1.